Medistep Healthcare IPO Listing at 4% Premium at ₹103 Per Share

Medistep Healthcare IPO listing: The Medistep Healthcare IPO was subscribed 382.14 times till its closing. In this subscription, [.] times were received by the qualified institutional buyers (QIBs) and 289.15 times by non-institutional investors (NIIs). The retail quota of the issue was subscribed to 47.52%. Before delving deeper into the topic, go through the details of the Medistep Healthcare IPO.

Medistep Healthcare IPO Listing

On the NSE and SME platform, Medistep Healthcare Limited is listed at ₹53 per share at a premium of 23% against the issue price of ₹43 per share.

About Medistep Healthcare IPO Details

Medistep Healthcare IPO: It is a bookbuilding IPO of ₹16.10 crore, comprising a fresh issue of 37.44 lakh shares. The issue will be listed on NSE and SME on its tentative listing date, 18th August 2025. The Medistep Healthcare IPO date is fixed between 8th August 2025 and 12th August 2025. The face value of Medistep Healthcare IPO shares stands at ₹10 per share, and the IPO price is set at ₹43 per share.

About Medistep Healthcare Limited

Medistep Healthcare Limited was incorporated in june 2023.Medistep Healthcare Limited is a pharmaceutical company that offers a variety of  health products that include sanitary pads, pharmaceutical products, nutraceutical products, personal care products, and surgical products. The company has a strong commitment towards excellence, high productivity, and a focus on delivering innovative healthcare products. Medistep Healthcare Limited has raised funds through its IPO for the expansion of its production capacity, innovative production, technology advancement, and quality assurance.

Medistep Healthcare Limited Financials

The company’s financial analysis is essential before applying for the Medistep Healthcare IPO. Look at the table to learn about Medistep Healthcare Limited’s financials. 

Explanation

Medistep Healthcare Limited’s revenue increased by 57% from ₹31.63 crores in March 2024 to ₹49.63 crores in March 2025. Moreover, the company’s PAT increased by 42% from ₹2.91 crores to ₹4.14 crores. Investors can analyse other relevant factors and make a decision accordingly.

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Regaal Resources IPO GMP: Day 2 IPO Live Updates